DENDRIMERS: ADVANCEMENTS IN NOVEL DRUG DELIVERY SYSTEM
DOI:
https://doi.org/10.22159/ijms.2026v14i1.56453Keywords:
Dendrimers, Drug delivery, Nanomedicine, physicochemical properties, Targeted drug administration, Dual-responsive nanoparticles, Solid tumors, Dendron-polymer conjugates, Controlled release, cancer, Neuroinflammation, Clinical translation, Cytotoxicity, Personalized medicine, Drug-resistant pathogensAbstract
Dendrimers exhibit unique physicochemical properties, such as internal cavities and surface functionality, that enhance their effectiveness as drug delivery vehicles, improving solubility and stability of therapeutics. Various dendrimer types, including dendritic polymers and hyper branched polymers, are discussed in terms of their customization for targeted drug administration. The study further evaluates the development of dual-responsive nanoparticles (PDPP@D), which demonstrate enhanced penetration in solid tumors, and explores dendron-polymer conjugates as nanosized drug delivery systems. The findings showcase dendrimers’ capability to encapsulate therapeutic agents, facilitating controlled release and improved efficacy in treating diseases such as cancer and neuroinflammation. In addition, the research highlights challenges in clinical translation, including issues of cytotoxicity and immune response, while underscoring the promise of dendritic structures in advancing personalized medicine and combating drug-resistant pathogens. Overall, this study contributes to the understanding of dendrimers in biomedical applications, emphasizing their role in innovative drug delivery systems and therapeutic strategies
References
1. Wang J, Li B, Qiu L, Qiao X, Yang H. Dendrimer-based drug delivery systems: History, challenges, and latest developments. J Biol Eng 2022;16:8.
2. Vögtle F, Richardt G, Werner N. Introduction. In: Vögtle F, Richardt G, Werner N, editors. Dendrimer Chemistry: Concepts, Syntheses, Proper Ties, Applications. United States: Wiley, 2009. p. 1-24
3. Buhleier E, Wehner W, Vögtle F. “Cascade”- and “nonskid- chain-like” syntheses of molecular cavity topologies. Synthesis 1978;9:155-8.
4. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, et al. A new class of polymers: Starburst-dendritic macromolecules. Polym J 1985;17:117-32.
5. Tomalia DA, Fréchet JM. Discovery of dendrimers and dendritic polymers: A brief historical perspective. J PolymSci A Polym Chem 2002;40:2719-28.
6. Liko F, Hindré F, Fernandez-Megia E. Dendrimers as innovative radiopharmaceuticals in cancer radionanotherapy. Biomacromolecules 2016;17:3103-14.
7. Launay N, Caminade AM, Lahana R, Majoral JP. A general synthetic strategy for neutral phosphorus-containing dendrimers. Angew Chem Int Ed Engl 1994;33:1589-92.
8. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discov Today 2010;15:171-85.
9. Rao BN, Viswanath V, Reddy KR, Fathima SR, Surekha P, Bhuvaneswari S. Dendrimers-structure, synthesis, encapsulation, characterization and application. J Global Trends Pharm Sci 2015;6:2860-6.
10. Kurtoglu YE, Mishra MK, Kannan S, Kannan RM. Drug release character istics of PAMAM dendrimer-drug conjugates with different linkers. Int J Pharm 2010;384:189-94.
11. Fox LJ, Richardson RM, Briscoe WH. PAMAM dendrimer - cell membrane interactions. Adv Colloid Interface Sci 2018;257:1-18.
12. Sadekar S, Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: Implications for oral drug delivery. Adv Drug Deliv Rev 2012;64:571-88.
13. Liu H, Wang Y, Wang M, Xiao J, Cheng Y. Fluorinated poly(propylenimine) dendrimers as gene vectors. Biomaterials 2014;35:5407-13.
14. Klajnert B, Appelhans D, Komber H, Morgner N, Schwarz S, Richter S, et al. The influence of densely organized maltose shells on the biological properties of poly(propylene imine) dendrimers: New effects dependent on hydrogen bonding. Chemistry 2008;14:7030-41.
15. Manikkath J, Hegde AR, Kalthur G, Parekh HS, Mutalik S. Influence of peptide dendrimers and sonophoresis on the transdermal delivery of ketoprofen. Int J Pharm 2017;521:110-9.
16. Sadler K, Tam JP. Peptide dendrimers: Applications and synthesis. J Biotechnol 2002;90:195-229.
17. Quintana S, García MÁ, Marina ML, Gomez R, De La Mata FJ, Ortega P. Synthesis of chiral carbosilanedendrimers with l-cysteine and N-acetyl-l- cysteine on their surface and their application as chiral selectors for enantiomer separation by capillary electrophoresis. Tetrahedron Asymmetry 2017;28:1797-802.
18. Pu L. Synthesis and study of binaphthyl-based chiral dendrimers. J Photochem Photobiol Chem 2003;155:47-55.
19. Serkova ES, Krasnova IY, Milenin SA, Selezneva EV, Tatarinova EA, Boldyrev KL, et al. Core/shell hybrid dendrimers: Controllable rigidity determines molecular behaviour. Polymer 2018;138:83-91.
20. Patel V, Rajani C, Paul D, Borisa P, Rajpoot K, Youngren-Ortiz SR, et al. Dendrimers as novel drug-delivery system and its applications. In: Drug Delivery Systems Drug. New York: Academic Press; 2020. p. 333-92.
21. Gurunathan S, Kang MH, Qasim M, Kim JH. Nanoparticle-mediated combination therapy: Two-in-one approach for cancer. J Mol Sci 2018;19:3264.
22. Mittal P, Saharan A, Verma R, Altalbawy FM, Alfaidi MA, Batiha GE, et al. Dendrimers: A new race of pharmaceutical nanocarriers. Biomed Res Int 2021;2021:8844030.
23. Gauro R, Nandave M, Jain VK, Jain K. Advances in dendrimer-mediated targeted drug delivery to the brain. J Nano Res 2021;23:76.
24. Zorab MM, Qadir AM, Ahmed AM. Dendrimers as drug delivery vehicles: A comprehensive review. Cell Mol Biol (Noisy-le-grand) 2025;71:1-12.
25. Koti N, Timalsena T, Kajal K, Worsley C, Worsley A, Worsley P, et al. Core-tunable dendritic polymer: A folate-guided theranostic nanoplatform for drug delivery applications. ACS Omega 2024;9:30544-58.
26. Zheng X, Pan D, Zhu G, Zhang L, Bhamra A, Chen R, et al. A dendritic polymer-based nanosystem mediates drug penetration and irreversible endoplasmic reticulum stresses in tumor via neighboring effect. Adv Mater 2022;34:e2201200.
27. Mandal AK. Dendrimers in targeted drug delivery applications: A review of diseases and cancer. Int J Polym Mater Polym Biomater 2021;70:287-97.
28. Tomalia DA. Dendrimers, dendrons, and the dendritic State: Reflection on the last decade with expected new roles in pharma, medicine, and the life sciences. Pharmaceutics 2024;16:1530.
29. Ray P, Ferraro M, Haag R, Quadir M. Dendritic polyglycerol-derived nano-architectures as delivery platforms of gemcitabine for pancreatic cancer. Macromol Biosci 2019;19:e1900073.
30. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004;114:1241-4.
31. Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol 2022;11:3.
32. Bolu BS, Sanyal R, Sanyal A. Drug delivery systems from self-assembly of dendron-polymer conjugates (†). Molecules 2018;23:1570.
33. Rajput MKS, Kesharwani SS, Kumar S, Muley P, Narisetty S, Tummala H. Dendritic cell-targeted nanovaccine delivery system prepared with an immune-active polymer. ACS Appl Mater Interfaces 2018;10:27589-602.
34. Pedziwiatr-Werbicka E, Milowska K, Dzmitruk V, Ionov M, Shcharbin D, Bryszewska M. Dendrimers and hyperbranched structures for biomedical applications. Eur Polym J 2019;119:61-73.
35. Sadjadi S, Sadjadi S. Dendritic polymers for environmental remediation. In: New Polymer Nanocomposites for Environmental Remediation. Netherlands: Elsevier; 2018. p. 279-335.
36. Gillies ER, Fréchet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005;10:35-43.
37. Contin M, Garcia C, Dobrecky C, Lucangioli S, D’Accorso N. Advances in drug delivery, gene delivery and therapeutic agents based on dendritic materials. Future Med Chem 2019;11:1791-810.
38. Romero JF, Herziger S, Cherri M, Dimde M, Achazi K, Mohammadifar E, et al. Dendritic glycerol-cholesterol amphiphiles as drug delivery systems: A comparison between monomeric and polymeric structures. Pharmaceutics 2023;15:2452.
39. Aida T, Meijer EW, Stupp SI. Functional supramolecular polymers. Science 2012;335:813-7. 40. Dong R, Zhou Y, Zhu X. Supramolecular dendritic polymers: From synthesis to applications. Acc Chem Res 2014;47:2006-16. Kallos GJ, Tomalia DA, Hedstrand DM, Lewis S, Zhou J. Molecular‐weight determination of a polyamidoamine Starburst polymer by electrospray ionization mass‐spectrometry Rapid Commun Mass Spectrom 1991;5:383-6.
41. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, et al. A new class of polymers: Starburst-dendritic macromolecules. Polym J 1985;17:117-32.
42. Tomalia DA, Durst HD. Supramolecular chemistry I-directed synthesis and molecular recognition. In: Weber E, editor. Topics in Current Chemistry. Vol. 165. Berlin: Springer-Verlag; 1993. p. 193-313.
43. Staudinger H. In From Organic Chemistry to Macromol-Ecules. New York: Wiley Interscience; 1970.
44. Hermes ME. In Enough for One Lifetime: WallaceCarothers. Inventor of Nylon. United States: American Chemical Society and Chemical Heritage Foundation; 1996.
45. Tomalia D, Frechet J. Discovery of dendrimers and dendritic polymers: A brief historical perspective. J Polym Sci Part A Polym Chem 2002;40:2719-28.
46. Pillai O, Panchagnula R. Polymers in drug delivery. Curr Opin Chem Biol 2001;5:447-51.
47. Newkome GR, Moorefield CN, Baker GR, Saunders MJ, Grossman SH. Unimolecular micelles. Angew Chem Int Ed Engl 1991;30:1178-80.
48. Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 2002;6:466-71.
49. Cuvier C, Roblot-Treupel L, Milliot JM, Lizard G, Chevillards S, Manfait M, et al. Doxorubicin-loaded nanospheres bypass tumour cell multidrug resistance. Biochem Pharmacol 1992;44:509-17.
50. Omelyanenko V, KopecˇKova´ P, Gentry C, Kopecek J. Targetable HPMA copolymer-adriamycin conjugates: Recognition, internalization, and subcellular fate. J Control Release 1998;53:25-37.
51. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjugate Chem 1992;3:351-62.
52. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995;31A:766-70.
53. Ihre HR, Padilla De Jesús OL, Szoka FC Jr., Fréchet JM. Polyester dendritic systems for drug delivery applications: Design, synthesis, and characterization. Bioconjug Chem 2002;13:443-52.
54. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005;4:581-93.
55. Kaminskas LM, Boyd BJ, Porter JH. Dendrimer pharmacokinetics: The effect of size, structure and surface characteristics on ADME propertie. Nanomedicine 2011;6:1063-84.
56. Kaminskas LM, Boyd BJ, Karellas P, Henderson SA, Giannis MP, Krippner GY, et al. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-L-lysine dendrimers. Mol Pharm 2007;4:949-61.
57. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000;65:133-48.
58. Wiwattanapatapee R, Carreño-Gómez B, Malik N, Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: A potential oral delivery system. Pharm Res 2000;17:991-8.
59. Yang Y, Sunoqrot S, Stowell C, Ji J, Lee CW, Kim JW, et al. Effect of size, surface charge, and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration. Biomacromolecules 2012; 13:2154-62.
60. Bugno J, Hsu HJ, Hong S. Recent advances in targeted drug delivery approaches using dendritic polymers. Biomater Sci 2015;3:1025-34.
61. Patel AV, Shah BN. Transdermal drug delivery system: A review. Pharma Sci Monit 2018;9: ???.
62. Begines B, Ortiz T, Pérez-Aranda M, Martínez G, Merinero M, Argüelles-Arias F, et al. Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials (Basel) 2020;10:1403.
63. Li H, Sun J, Zhu H, Wu H, Zhang H, Gu Z, et al. Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1670.
64. Calik F, Degirmenci A, Eceoglu M, Sanyal A, Sanyal R. Dendron-polymer conjugate based cross-linked micelles: A robust and versatile nanosystem for targeted delivery. Bioconjug Chem 2019;30:1087-97.
65. Singh S. Nanomedicine-nanoscale drugs and delivery systems. J Nanosci Nanotechnol 2010;10:7906-18.
66. Pandya A, Shah Y, Kothari N, Postwala H, Shah A, Parekh P, et al. The future of cancer immunotherapy: DNA vaccines leading the way. Med Oncol 2023;40:200.
67. O’Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release 2021;336:144-58.
68. Kharia A, Singhai AK, Gilhotra R. Formualtion and evalaution of transdermal patch for the treatment of inflammation. J Pharm Sci Res 2020;12:780-8.
69. Ramesh M, Janani R, Deepa C, Rajeshkumar L. Nanotechnology-enabled biosensors: A review of fundamentals, design principles, materials, and applications. Biosensors (Basel) 2022;13:40.
70. Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: Structure, composition, types, and clinical applications. Heliyon 2022;8:e09394.
71. Shah M, Agrawal Y. Carbon nanotube: A novel carrier for sustained release formulation. Fullerenes Nanotubes Carbon Nanostructures 2012;20:696-708.
72. Perumal S, Atchudan R, Lee W. A review of polymeric micelles and their applications. Polymers (Basel) 2022;14:2510.
73. Moscicki AB, Kaul R, Ma Y, Scott ME, Daud II, Bukusi EA, et al. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% SPL 7013 gel (VivaGel®) to assess expanded safety. J Acquir Immune Defic Syndr 2012;59:134-40.
74. Gosselin RC, Wu JR, Kottke-Marchant K, Peetz D, Christie DJ, Muth H, et al. Evaluation of the stratus CS acute care D-dimer assay (DDMR) using the stratus CS STAT fluorometric analyzer: A prospective multisite study for exclusion of pulmonary embolism and deep vein thrombosis. Thromb Res 2012;130:e274-8.
75. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): A candidate dendrimer--microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2007;2:561-6.
76. Akhtar S, Chandrasekhar B, Attur S, Yousif MH, Benter IF. On the nanotoxicity of PAMAM dendrimers: Superfect® stimulates the EGFR-ERK1/2 signal transduction pathway via an oxidative stress-dependent mechanism in HEK 293 cells. Int J Pharm 2013;448:239-46.
77. LifeScience A. M IPO.
78. Available from: https://patents.google.com/patent/us10842758b1// en?q=(transdermal)&oq=transdermal+
79. Availablef rom:h ttps://patents.google.com/patent/US2024028579/7A1/ en?q=(Nanocarrier)&oq=Nanocarrier+
80. Available from:https://patents.google.com/patent/us2022017587/4a1/ en?q=(polymeric+nanoparticles)&oq=polymeric+n anoparticles+
81. Available from: https://patents.google.com/patent/us12017188b2// en?q=(dendritic+polymer+nanoparticles)&oq=dendritic+ polymer +nanoparticles+
82. Available from: https://patents.google.com/patent/us8747904b2/e/ n?q=(micelles)&oq=micelles+
83. Available from: https://patents.google.com/patent/ca2994958c/ en/?inventor=asmamaw+wassie
84. Available from: https://patents.google.com/patent/us7749979b2/e/ n?q=(dna+vaccine)&oq=dna+vaccine+
85. Available from: https://patents.google.com/patent/us11707507b2// en?q=(injectable+solution)&oq=injectable+solution+
Published
How to Cite
Issue
Section
Copyright (c) 2026 SAYALI V. KHALADKAR, RUTUJA A. RAHATAL, RAKSHA LAXMAN MHETRE, NILESH S. KULKARNI, SHASHIKANT N. DHOLE
This work is licensed under a Creative Commons Attribution 4.0 International License.